arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

BIOADAPTIVES, INC.

BDPT
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
41 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
60
Health
Fair
Bullish
auto_awesome

Analytical Summary

BIOADAPTIVES, INC. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth 55.0%
Op. Margin None
ROIC 8.8% ↗
FCF / Share $-0.00
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

41-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.99K
↑ +55.0% —
Net Income Profit after all expenses
$-111.09K
↑ +43.7% —
Operating Margin Operating profit as % of sales
-415.5%
↓ -88.6% —
FCF / Share Free cash flow per share
$-0.00
↑ +73.1% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns ↓
98
Financial Health ↓
27
Cash Quality ↑
34

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 41 quarters